Vye Ventures

Bolt Graphics is a semiconductor startup focused on developing advanced graphics processors (GPUs) designed to address the growing demand for performance and efficiency in various industries, including architecture, engineering, film, advertising, gaming, and scientific research. With rising power consumption and minimal performance improvements in existing hardware, the company aims to revolutionize the rendering process through its innovative hardware-accelerated platform. This platform features a hardware ray tracing pipeline that provides fast and flexible performance, significantly reducing the time creators spend waiting for renders. By prioritizing performance and power efficiency, Bolt Graphics enables game developers, visual effects artists, and other content creators to bring their ideas to life more quickly and sustainably.

Melio is a healthcare company based in Santa Clara, California, specializing in blood testing technology aimed at detecting prevalent infections. The company has developed a comprehensive blood test platform that identifies common pathogens responsible for bloodstream infections. Utilizing a patented melting technique followed by detailed analysis, Melio's technology enables quick and accurate identification of blood-based pathogens. This innovation allows healthcare providers to deliver timely and targeted treatment, addressing the urgent need for effective therapies while also contributing to the fight against antibiotic resistance.

Oatmeal Health is a pioneering virtual cancer clinic that focuses on delivering high-quality, patient-centered care through the integration of AI technology. The organization supports patients in Community Health Centers, Health Systems, and Imaging Centers by utilizing nurse practitioners and AI agents. Its services encompass a wide range of offerings, including lung cancer screenings, risk assessments, diagnosis, care navigation, and educational resources aimed at saving lives. By developing a multispecialty primary care and radiology platform, Oatmeal Health aims to enhance cancer screening and care for underserved populations, providing innovative virtual and on-site services. These services include AI-driven patient identification and matching, as well as AI-nodule risk assessments, ultimately empowering medical professionals to deliver preventative, image-based cancer screening at scale.

Lutroo Imaging focuses on advancing the diagnosis of chronic pain through innovative imaging technology. The company is developing a patented PET radiotracer that offers a novel method for visualizing pain, aiming to enhance the accuracy and speed of pain diagnosis. This approach utilizes artificial intelligence in molecular imaging diagnostics, allowing healthcare professionals to better diagnose and quantify pain in patients. By improving diagnostic processes, Lutroo Imaging seeks to significantly benefit the lives of the one in five adults worldwide who suffer from chronic pain.

Keyo Inc., established in 2017 and headquartered in Palo Alto, California, specializes in biometric identification technology. The company offers a consent-based, privacy-focused global identity network, enabling users to perform various tasks such as payments, door unlocking, and identification using a contactless palm scan. Keyo's patented hardware and software map the unique vein patterns in the palm, converting them into a secure, encrypted key that is virtually unbreakable and cannot be used to reverse engineer biometric data.

American Gene Technologies International Inc., established in 2007 and based in Rockville, Maryland, is a biotechnology company specializing in gene and cell therapeutics. It develops a lentiviral platform with broad applications, including large and orphan indications, infectious diseases, immuno-oncology, and monogenic disorders. The company's portfolio includes a lead candidate for an HIV functional cure, a novel immuno-oncology approach to stimulate gamma-delta T cells, and a synthetic gene for treating Phenylketonuria (PKU). AGT aims to create long-term value for patients, society, and investors by developing and testing cutting-edge gene therapies to cure some of humanity's worst diseases.

MD.ai is a developer of a comprehensive medical AI platform aimed at transforming healthcare through the application of artificial intelligence, particularly in medical imaging. The platform integrates machine learning with the expertise of human radiologists to analyze medical images, providing assessments and recommendations on significant findings. By offering data annotation and model development tools, MD.ai facilitates collaboration among clinicians, researchers, data scientists, and engineers. This collaborative approach aims to accelerate the development and implementation of impactful medical AI solutions, ultimately enhancing patient care and driving improvements in efficiency and cost-effectiveness within the healthcare system.

Lutroo Imaging focuses on advancing the diagnosis of chronic pain through innovative imaging technology. The company is developing a patented PET radiotracer that offers a novel method for visualizing pain, aiming to enhance the accuracy and speed of pain diagnosis. This approach utilizes artificial intelligence in molecular imaging diagnostics, allowing healthcare professionals to better diagnose and quantify pain in patients. By improving diagnostic processes, Lutroo Imaging seeks to significantly benefit the lives of the one in five adults worldwide who suffer from chronic pain.

Loopie is a laundry delivery service that leverages a peer-to-peer managed marketplace model to offer a fast and cost-effective alternative to traditional wash and fold services. Founded in 2018 in Seattle, Loopie's innovative platform transforms idle washers and dryers into revenue-generating assets by connecting consumers and businesses with certified laundry providers. The service enables users to have their laundry picked up, washed, dried, folded, and delivered within hours, enhancing convenience and efficiency. Since its launch, Loopie has successfully expanded to six additional markets and has achieved over $1.25 million in early sales, supported by more than $2.25 million in early-stage and venture capital funding.